Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. - Wikidata - awgldk - TriplyDB

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

http://www.wikidata.org/entity/Q37095019

about

The Potential of Pharmacogenomics to Advance Kidney Disease Treatment.

P2860

Q55429154-28183CBA-99D9-4682-B332-0340A56CE888

P2860

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

http://www.wikidata.org/entity/Q37095019

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacogenetic analysis of ci ...... hyperparathyroidism patients.

@en

Pharmacogenetic analysis of ci ...... hyperparathyroidism patients.

@nl

type

label

Pharmacogenetic analysis of ci ...... hyperparathyroidism patients.

@en

Pharmacogenetic analysis of ci ...... hyperparathyroidism patients.

@nl

prefLabel

Pharmacogenetic analysis of ci ...... hyperparathyroidism patients.

@en

Pharmacogenetic analysis of ci ...... hyperparathyroidism patients.

@nl

P1433

Q37095019-515D6CFB-0137-4E5F-ABC0-6D48C0DDB475

P1476

Q37095019-E048676B-3F4C-4B80-B21F-D7E0BB79A014

P2093

Q37095019-52E683D9-FED4-480D-AAE2-A2D6807160D5

Q37095019-61C33E8B-B61C-4AB1-B255-1B239C3A71D0

Q37095019-697AB78D-9CCD-4649-A631-4F26E15F820A

Q37095019-6DFADAAC-EBD8-485B-9FC4-58540F8CD7F0

Q37095019-778703D8-AA38-4D89-AFD5-FC58FFD018FC

Q37095019-BA20CD36-A52E-4D37-A056-A1B6DCD9EB1D

Q37095019-F7D456B2-129F-409E-A462-AA85E7952D71

P2860

Q37095019-02A984E5-2AA9-4660-BF77-A224AF76030C

Q37095019-06F13D4F-3C62-4E04-8C4B-FA8FA5055FDC

Q37095019-092DBEEB-FF1B-4A46-A0FF-8C8484B0E304

Q37095019-0959EED6-9662-4835-94D2-F00026BE288A

Q37095019-0AFD1920-B1D8-4859-977C-155FE25299A1

Q37095019-0B41B27F-465B-4580-B64F-0586D5951B55

Q37095019-156C9507-F061-4821-A11F-30BFC1EF9C33

Q37095019-180C6A42-EC55-4927-826F-F3FA509852A9

Q37095019-1C8C5788-1C72-471D-AC7A-E3EB0A206C70

Q37095019-1CAD5C3C-9955-4876-B3D7-0B30F6413B0A

P304

Q37095019-7AAB0922-6878-4B30-ADBC-4AD79B8F4CC9

P31

Q37095019-E024FF21-A5C8-4F17-AEA1-58EB84E5F82B

P356

Q37095019-53329E5D-5EB7-4A0B-8FED-9AE31A6FE30E

P407

Q37095019-B7D8FCF8-ADC7-4043-8C5D-0029ED8311FE

P478

Q37095019-F1918E98-8819-4306-861F-29D2321B4959

P577

Q37095019-4546086C-6237-4B52-9CE2-BBAC061BD1AB

P698

Q37095019-C0A0C361-2604-4550-9016-1B9A3C554D61

P921

Q37095019-F80CF9A8-D6ED-40DA-BB78-45638ECAB0A6

P932

Q37095019-50166C0D-7032-424A-9E52-AA7418FB849F

P356

P1433

Drug Design, Development and Therapy

P1476

Pharmacogenetic analysis of ci ...... hyperparathyroidism patients.

@en

P2093

Hyo Jin Kim

http://www.w3.org/2001/XMLSchema#string

In-Wha Kim

http://www.w3.org/2001/XMLSchema#string

Jung Mi Oh

http://www.w3.org/2001/XMLSchema#string

Kook-Hwan Oh

http://www.w3.org/2001/XMLSchema#string

Kwon Wook Joo

http://www.w3.org/2001/XMLSchema#string

Nayoung Han

http://www.w3.org/2001/XMLSchema#string

Sohyun Jeong

http://www.w3.org/2001/XMLSchema#string

P2860

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

Parathyroid hormone induces expression of the nuclear orphan receptor Nurr1 in bone cells.

Two types of amino acid substitutions in protein evolution.

Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements

The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.

Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends.

Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era.

P304

2211-2225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S103370

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27468225

http://www.w3.org/2001/XMLSchema#string

P921

hyperparathyroidism

P932

4944925

http://www.w3.org/2001/XMLSchema#string